AMGN Stock Amgen Inc.
US · NasdaqGSLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Diversified biologics portfolio and obesity pipeline create upside while dividend supports downside.
Future value: $396.70 (-9.69%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Obesity pipeline catalyst and steady cash returns.
- ▸Above 50-day MA (+5.27%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (92.8% of range) — strength
- ▾Trading above its price target — limited upside
Is AMGN a buy right now?
Trend: AMGN is trading above the 50-day average (+6.41%), RSI 45 — neutral momentum, with a 3-month return of +13.11%.
Valuation & quality: Amgen Inc. trades on a trailing P/E of 27.6, forward P/E 18.2, PEG 2.62, price-to-book 20.57; fundamentals show net margin 23.0%, return on equity 91.5%, revenue growth 9.5% year on year.
Analyst consensus: 29 analysts have a mean 12-month price target of $397.32 (-10.6% vs the last close; range $225.00 – $500.00), consensus rating “hold”.
Income: trailing dividend yield 2.29%.
Our screen: BUY (score 2) — Diversified biologics portfolio and obesity pipeline create upside while dividend supports downside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.40% | -1.60% | -2.70% | +7.50% | +6.40% | +11.60% | -1.90% | +5.50% |
Fundamentals
Analyst price target
Technical signals
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 31,500 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.